Critical Analysis: Decoy Therapeutics (DCOY) & Its Peers

Decoy Therapeutics (NASDAQ:DCOY) is one of 458 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it compare to its competitors? We will compare Decoy Therapeutics to related businesses based on the strength of its valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Risk & Volatility

Decoy Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Decoy Therapeutics’ competitors have a beta of 5.42, indicating that their average stock price is 442% more volatile than the S&P 500.

Valuation and Earnings

This table compares Decoy Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Decoy Therapeutics	N/A	-$5.58 million	-0.02
Decoy Therapeutics Competitors	$432.07 million	-$67.78 million	-10.57

Decoy Therapeutics’ competitors have higher revenue, but lower earnings than Decoy Therapeutics. Decoy Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 0.3% of Decoy Therapeutics shares are owned by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Decoy Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-401.05%	-155.77%
Decoy Therapeutics Competitors	-2,662.14%	-363.93%	-42.95%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Decoy Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1	0	1	0	2.00
Decoy Therapeutics Competitors	4898	9967	15993	376	2.38

Decoy Therapeutics currently has a consensus target price of $2.50, indicating a potential upside of 253.11%. As a group, “Pharmaceutical Preparations” companies have a potential upside of 61.15%. Given Decoy Therapeutics’ higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than its competitors.

Summary

Decoy Therapeutics competitors beat Decoy Therapeutics on 9 of the 13 factors compared.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.